Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topiramate for reducing methamphetamine craving
IRCT20180929041167N1Phase 3Completed
- Sponsor
- Iran University of Medical Sciences
- Start
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in methamphetamine use disorder (MUD) comparing Topiramate + matrix model therapy with Placebo + matrix model therapy (2 arms). Primary endpoints: Positive urine test for methamphetamine, Stimulant Craving Questionnaire score and 1 more. Started Jul 2019; status: completed.
02
Drugs
topiramate
03
Conditions
methamphetamine use disorder (MUD)
Beyond the preview
Go deeper on IRCT20180929041167N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20180929041167N1.